We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
-5.05%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.37B
AUM Growth
-$155M
Cap. Flow
-$860M
Cap. Flow %
-25.49%
Top 10 Hldgs %
37.46%
Holding
92
New
13
Increased
23
Reduced
14
Closed
19

Top Buys

Rank Stock Value
1
TMDX icon
Transmedics
TMDX
+$85.8M
2
KROS icon
Keros Therapeutics
KROS
+$61.7M
3
LEGN icon
Legend Biotech
LEGN
+$59.5M
4
TMO icon
Thermo Fisher Scientific
TMO
+$49.3M
5
GERN icon
Geron
GERN
+$28M

Top Sells

Rank Stock Value
1
PEN icon
Penumbra
PEN
+$40.4M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$39M
3
ARVN icon
Arvinas
ARVN
+$31.6M
4
APLS
Apellis Pharmaceuticals
APLS
+$30.9M
5
DXCM icon
DexCom
DXCM
+$29.6M

Sector Composition

Rank Sector Weight
1 Healthcare 66.36%
2 Miscellaneous 33.64%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLAY icon
76
Relay Therapeutics
RLAY
$4.11B
– –
-3,499,427
Closed -$24.8M
SKIN icon
77
SkinHealth Systems
SKIN
$89.1M
– –
-4,049,694
Closed -$5.83M
VERV
78
DELISTED
Verve Therapeutics
VERV
– –
-623,980
Closed -$3.02M
1 2 3
4

Similar funds

CWM
Connecticut Wealth Management Farmington, Connecticut $2.7B AUM 21.91% 1-Year Est. Return
M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM

Braidwell's Q4 2024 Portfolio in Review

As of Q4 2024, Braidwell held 92 positions worth $3.37B, down 4.4% from $3.53B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Braidwell withdrew a net $860M in Q4 2024, closing 19 positions and reducing 14 holdings. Its most notable exit was Madrigal Pharmaceuticals, an estimated $39M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 66% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Braidwell opened a new position in Transmedics worth $57.5M.

  • Braidwell's largest Q4 2024 buy was Transmedics: 922,100 shares worth $57.5M.
  • Braidwell added most to Keros Therapeutics in Q4 2024, an estimated $61.7M increase.
  • Braidwell's biggest Q4 2024 reduction was Penumbra, cutting an estimated $40.4M.
  • Braidwell fully exited Madrigal Pharmaceuticals in Q4 2024, selling an estimated $39M.
  • Braidwell's ten largest holdings make up 37% of its $3.37B portfolio in Q4 2024.
  • Braidwell opened 13 new positions and closed 19 in Q4 2024.
  • Braidwell's portfolio value fell 4.4% quarter-over-quarter to $3.37B.

Based on Braidwell's 13F filing for Q4 2024, filed 14 Feb 2025.